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In light of current events, the recent
publication of the complete genomic
sequence of the bacterium Yersinia
pestis was guaranteed to be greeted
with interest, even if it hadn’t
presented us with a whole set of
mysteries to solve about the plague
pathogen’s genome. But the fact is
that Yersinia pestis — the causative
agent of the medieval Black Death
and the bug that’s claimed an
estimated 200 million lives since the
Dark Ages — has a genome that
would garner interest even in less
germ-conscious times than these.
The sequence of the chromosome
and 3 plasmids of Y. pestis strain
CO92, which was completed by a
group lead by Julian Parkhill at the
Sanger Centre, features evidence of a
dynamic genome rich in insertion
sequences and intragenomic
rearrangements, and including
numerous signs of horizontal gene
acquisition (see Nature 413:523-527).  
At the forefront of issues that can
now be addressed regarding Y. pestis
biology are long-standing questions
about its evolutionary history. It has
been recognized for some time that
Y. pestis, a blood-borne pathogen that
causes systemic disease that is
usually fatal if left untreated, is
actually a very close relative of
Yersinia pseudotuberculosis, an
enteropathogen that causes typically
non-fatal gut disease (the two species
are thought to have diverged only
1,500–20,000 years ago). A relatively
distant ancestor of both species,
Yersinia enterocolitica also causes non-
fatal gut disease. The enigma is that
Y. enterocolitica is genetically so much
further removed from Y. pseudo-
tuberculosis than is Y. pestis, says
Brendan Wren of the Sanger Centre,
one of the team that sequenced Y.
pestis. “You have two species that
cause very similar disease outcomes
but are more distantly related, and
yet the two that are more closely
related cause very different disease
outcomes.” 
The key to solving the enigma, of
course, is to undertake some in-depth
comparative genomic studies between
the species, especially between Y.
pestis and Y. pseudotuberculosis. Central
to this effort will be the availability of
the full Y. pseudotuberculosis genome
sequence, a resource made possible
by a collaboration between Emilio
Garcia’s group at Lawrence Livermore
National Lab in California and
Elisabeth Carniel’s team at Institut
Pasteur. Sequencing of Y. pseudo-
tuberculosis, which has been done at
Livermore, is now complete and
annotation is under way, according to
Garcia. In the meantime comparative
studies have already begun to
characterize points of genetic
distinction between the species, and
major differences, like the presence of
two Y. pestis-specific plasimds, are
well-known. These pestis-specific
plasmids appear to be rich in
virulence factors, but apparently don’t
account for the species differences on
their own. “If you move these
plasmids back to Y. pseudotuberculosis,
you don’t make Y. pestis,” says Garcia.
“So the idea is that something in the
chromosome is involved.” 
As is typically the case in
comparative studies, figuring out
which differences are evolutionarily
and functionally significant will be a
major challenge. Once genetic
discrepancies are found between the
two species, their relevance to
virulence and other phenotypes is
tested by knocking out function, but
only those differences that are
consistent between species, and not
representative of mere strain
differences, will be of real value in
understanding the evolution and
distinct biology of Y. pestis and
Y. pseudotuberculosis. So as the
Livermore group and their
collaborators find sequence
differences between the strains, they
are also doing targeted resequencing
from some of the hundreds of Y. pestis
and Y. tuberculosis strains available.
A point of particular interest will
be the nearly 150 pseudogenes found
in the Y. pestis sequence that appear
to represent functions that have been
retained by Y. pseudotuberculosis.
According to Michael Prentice of
St. Bartholomew’s Hospital in
London, a Sanger group collaborator,
about 15 of these genes — including
those that aid adhesion to gut cells
and survival in acidic conditions —
were already known to be virulence
factors in Y. pseudotuberculosis.
Learning the roles of the other 130
candidates should prove useful not
only in understanding enteric
microbial pathogenesis, but also how
Y. pestis pulled off the major switch
from a water-borne enteric lifestyle
to one in which it shuttles
successfully between fleas and the
bloodstreams of mammals.  
That latter question remains
somewhat mysterious, though the
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many telltale signs of lateral gene
transfer found in the Y. pestis
sequence suggest how the plague
virulence factors likely arrived in the
genome. The next step is
understanding the roles these various
factors play in allowing Y. pestis to
occupy its flea/mammal niche.
Researchers are eager to identify
genes and regulatory circuits that are
specifically controlled in response to
changing environmental conditions
and infection, and now that the
sequence is complete there are
numerous groups gearing up to create
Y. pestis microarrays and commence
expression studies. 
Some technological barriers will
need to fall before sophisticated
in vivo experiments are possible: 
as the plague bacillus lacks a hardy
cell wall, it can’t survive the
relatively stringent purification
procedures required to isolate
significant amounts of bacterial 
RNA from infected mammalian
tissue, so the first generations of 
array studies will likely explore
regulatory events connected to
various environmental stimuli in
culture, and infection of tissue
culture cells. 
Finally, there’s more Yersinia
genome sequence soon to come in
addition to the Y. pseudotuberculosis
and Y. enterocolitica sequences. A
team lead by Fred Blattner at the
University of Wisconsin has
sequenced Y. pestis KIM5, a widely
studied strain of the Medaevalis
biovar thought to be the version
responsible for the medieval plague.
Close comparison of this strain and
the multi-drug resistant strain of
Y. pestis sequenced by the Sanger
group should offer valuable clues
about pathogenicity and drug
resistance, and how the apparent
dynamism of the Y. pestis genome
may influence its rapid evolution.
What’s ultimately on the horizon,
says Sanger team collaborator Rick
Titball of Porton Down, is using
what’s learned from the full sequence
and genomic studies to reconstruct
These days it’s reassuring to know
that somewhere in the Washington
DC area anthrax bacteria are being
put to good use. The place is The
Institute for Genomic Research
(TIGR), where the effort to
sequence and annotate the 4.5 Mb
Bacillus anthracis genome (Ames
strain) has been ongoing since 
well before September 11.
According to TIGR president
Claire Fraser, the project is well
into closure and should be
published within a few months. In
addition, TIGR has now been
funded by the National Science
Foundation to sequence to
approximately 6-fold coverage an
anthrax isolate from one of the
recent deliberate infections in
Florida. This project is already
underway, according to group
leader Timothy Read. 
Meanwhile other groups are
bringing innovative genomic
techniques to the use of the
B. anthracis sequence already
available. John Yates of the Scripps
Research Institute is using a gel-
less 2D liquid chromatography/
mass spectroscopy technique to
characterize changes in the
proteome during particular cellular
events in the bacterium, focusing at
the moment on germination. Yates
is working the proteomics side of a
collaboration with Phil Hanna at
the University of Michigan, and
Scott Peterson of TIGR, who is
looking at germination in parallel
with Yates, but at the RNA
expression level using microarrays. 
Of course look out for array-
based expression analyses of
infected host cells to prove
valuable in upcoming work as well,
given that the intracellular events
following contact with anthrax
lethal factor are not well
understood. John A.T. Young of the
University of Wisconsin, who led
the team who very recently
identified the cellular receptor for
anthrax toxin, recognizes the
potential of this approach at this
particular stage: “We have a
receptor, and we have a ligand that
activates that receptor — we can
actually do these experiments
quite cleanly now.”
Life threatening: Coloured scanning
electron micrograph of a section of lung
tissue infected with anthrax bacteria.
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The efficient development of
effective vaccines and therapeutics is
perhaps the most challenging of the
myriad promises of post-genomic
biology. Fortunately, as the list of
sequenced bacterial pathogens
grows, so does the opportunity to use
whole genome sequence as a
potentially powerful tool in vaccine
development. 
According to Rino Rappuoli, vice
president of vaccine research at
Chiron, genomic approaches can be
valuable alternatives to conventional,
largely empirical approaches,
especially in cases where strain
variations in surface protein
sequences and cross-reactivity with
human proteins have proven to be
stumbling blocks. Rappouli’s group
published pioneering work last year
in which unassembled genomic
sequence from a virulent Group B
Neisseria meningiditis strain was used
to identify surface-expressed and
exported proteins as novel, conserved
vaccine targets (Science
287:1816-1820). Work using a similar
approach to mine Streptococcus
pneumoniae sequence data was
published earlier this year (Infection
and Immunity 69:1593-1598). Many
other genome-based studies appear
Sequence paves way for new vaccines
Fresh efforts to develop new
vaccines and build stockpiles has
thrown a lifeline to one British
biotech company. Founded by
scientists at Birmingham
University, the company is
spearheading America’s response to
the threat of terrorist attack with
smallpox. Acambis, which has its
headquarters in Cambridge, has
now installed armed security
guards at its laboratories in
Massachusetts after unexpectedly
finding itself in the spotlight since
the events of September 11. 
Developments, however,
predate these events. The company,
which has 160 employees, answered
an advertisement in a trade
newspaper over two years ago to
supply vaccines for stockpiles
maintained by the US Centres for
Disease Control and Prevention. It
won a $343 million deal last year to
supply 40 million doses of its novel
smallpox antidote which was still
undergoing tests. The Americans
were worried that smallpox might
get into the hands of terrorists and
decided to build a stockpile just in
case.
Since September 11, the US
health secretary, Tommy
Thompson, has increased the
contract to 54 million doses and
asked Acambis to bring forward
delivery from 2004 to 2002. He has
even mooted the possibility of
providing an insurance indemnity
to cover side effects, so that
Acambis could speed up
development and need not
complete all the usual clinical
trials. 
Formerly known as Peptide
Therapeutics, the company’s
highest profile project to date was a
drug to reduce the severity of
peanut allergies, which raised the
visibilty of the company,
particularly in the US, but it has so
far not made a profit.
Major pharmaceutical
companies stopped making
smallpox vaccine in the 1980s,
when the world was declared free
of the natural disease. The
traditional vaccine was developed
from cowpox - the cattle version of
the disease. Scrapings from cows
stomachs were a source of vaccine
right up to the 1980s. But Acambis
has developed a way of producing
vaccines using cell cultures in the
laboratory which it is keeping
closely under wraps. Birmingham
University, which no longer has a
stake in Acambis, is set to miss out
on the changed prospects of one of
its spin-off companies.
Business boost
the bacterial cell in silico and
predicting the pathogen’s behavior in
different environments. “Clearly that
has to be the long-term goal — to
understand how all these gene
products interact with each other.”
under way, including work on
tuberculosis, malaria, staphylococcus
and chlamydia. 
Ongoing work on plague vaccines
at the UK’s Porton Down facility
illustrates the shift in strategy being
undertaken. A group lead by Rick
Titball has recently seen the
successful completion of phase I
trails by a plague vaccine developed
using relatively empirical approaches
to identifying surface antigens. But
now that the Yersinia pestis genome
sequence is complete the group plans
to use some novel algorithms they’ve
developed this year to mine
sequence data for new, alternative
vaccine targets. Using somewhat
different criteria than have been
conventionally used in such in silico
approaches, the group has come up
with “some very promising leads,”
for new targets, says Titball, who also
points out that the benefits of the
approach could extend to predicting
targets for biodetection systems and
antimicrobial intervention.
